Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs.

Eisele L, Günther F, Ebeling P, Nabring J, Dührsen U, Dürig J.

Onkologie. 2010;33(12):658-64. doi: 10.1159/000322209. Epub 2010 Nov 26.

PMID:
21124036
2.

Outpatient supportive care following chemotherapy for acute myeloblastic leukemia.

Allan DS, Buckstein R, Imrie KR.

Leuk Lymphoma. 2001 Jul;42(3):339-46.

PMID:
11699398
3.

Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.

Girmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L, Spadea A, Tosti S, Mecarocci S, D'Elia GM, Tafuri A, Cimino G, Mandelli F.

Haematologica. 1999 Sep;84(9):814-9.

5.

A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study.

Cancer. 2005 Dec 15;104(12):2726-34.

6.
7.

Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.

Saini L, Minden MD, Schuh AC, Yee KW, Schimmer AD, Gupta V, Atenafu EG, Murray C, Nixon S, Brandwein JM.

Am J Hematol. 2012 Mar;87(3):323-6. doi: 10.1002/ajh.22268. Epub 2011 Dec 27.

8.

Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.

Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.

JAMA Oncol. 2015 Nov;1(8):1120-7. doi: 10.1001/jamaoncol.2015.2969.

PMID:
26355382
9.

Shifting to outpatient management of acute myeloid leukemia: a prospective experience.

Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC.

Ann Oncol. 2006 May;17(5):763-8. Epub 2006 Feb 23.

10.

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.

11.

[Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].

Creutzig U, Zimmermann M, Reinhardt D, Lehrnbecher T.

Klin Padiatr. 2003 May-Jun;215(3):151-8. German.

PMID:
12778355
12.

[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].

Fujiwara M, Satou N, Izumi N, Shibasaki Y, Higashimura M, Tsukada N, Koike T.

Gan To Kagaku Ryoho. 2007 Nov;34(11):1793-8. Japanese.

PMID:
18030012
13.

Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.

Harousseau JL, Milpied N, Briere J, Desablens B, Le Prise PY, Ifrah N, Gandhour C, Casassus P.

Haematol Blood Transfus. 1990;33:299-303. No abstract available.

PMID:
2323633
14.
15.
16.

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B, Gandemer V, Schmitt C, Lamagnere JP, De Lumley L, Bader-Meunier B, Couillaud G, Schaison G, Landman-Parker J, Thuret I, Dalle JH, Baruchel A, Leverger G; Group LAME of the French Society of Pediatric Hematology and Immunology.

J Clin Oncol. 2002 Jun 15;20(12):2774-82.

PMID:
12065553
18.

Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.

Grigg AP, Reynolds J, McQuillan A, Juneja SK, Di Iulio J, Hui C, Smith C, Kimber R, Bradstock KF; Australasian Leukaemia and Lymphoma Group.

Leuk Lymphoma. 2005 Mar;46(3):367-75.

PMID:
15621826
19.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.

PMID:
12928754
20.

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.

Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN.

Cancer. 2000 May 1;88(9):2037-41.

PMID:
10813714
Items per page

Supplemental Content

Write to the Help Desk